Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart.
Abstract: No abstract available
Publication Date: 2022-09-07 PubMed ID: 36066856PubMed Central: PMC9952875DOI: 10.1164/rccm.202208-1639EDGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Editorial
- Comment
- Clinical Pathology
- Clinical Study
- Clinical Symptoms
- Diagnosis
- Disease
- Disease Diagnosis
- Disease Etiology
- Disease Management
- Disease Treatment
- Equine Health
- Fibrosis
- Horses
- Pathophysiology
- Pulmonary Health
- Respiratory Disease
- Respiratory Health
- Veterinary Care
- Veterinary Medicine
- Veterinary Practice
- Veterinary Research
Cite This Article
APA
Cottin V.
(2022).
Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart.
Am J Respir Crit Care Med, 207(1), 11-13.
https://doi.org/10.1164/rccm.202208-1639ED Publication
Researcher Affiliations
- National Reference Centre for Rare Pulmonary Diseases Louis Pradel Hospital, Hospices Civils de Lyon Lyon, France.
- UMR 754, Institut national de recherche agronomique et environnement Claude Bernard University Lyon 1 Lyon, France.
MeSH Terms
- Horses
- Animals
- Pulmonary Fibrosis
References
This article includes 23 references
- Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. Am J Respir Crit Care Med 2022 May 1;205(9):e18-e47.
- Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What's in a name? That which we call IPF, by any other name would act the same.. Eur Respir J 2018 May;51(5).
- Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases.. Eur Respir J 2020 Jun;55(6).
- Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases.. N Engl J Med 2020 Sep 3;383(10):958-968.
- Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The Burden of Progressive-Fibrosing Interstitial Lung Diseases.. Front Med (Lausanne) 2022;9:799912.
- Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.. Am J Respir Crit Care Med 2003 Sep 1;168(5):531-7.
- Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, Kitaichi M, Colby TV. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.. Am J Respir Crit Care Med 2005 Mar 15;171(6):639-44.
- Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.. Am J Respir Crit Care Med 2013 Sep 15;188(6):733-48.
- Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.. Eur Respir J 2016 Feb;47(2):588-96.
- Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.. Arthritis Rheumatol 2017 Aug;69(8):1670-1678.
- Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.. N Engl J Med 2019 Oct 31;381(18):1718-1727.
- Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.. Lancet Respir Med 2020 May;8(5):453-460.
- Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).. Eur Respir J 2021 Feb;57(2).
- Takei R, Brown KK, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Suzuki A, Furukawa T, Fukuoka J, Johkoh T, Goto Y, Kondoh Y. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.. Respirology 2022 May;27(5):333-340.
- Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.. Eur Respir J 2022 Oct;60(4).
- Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, Tonkin J, Seede H, Echt G, Adegunsoye A, Chua F, Maher TM, Garcia CK, Strek ME, Newton CA, Molyneaux PL. Lung function trajectory in progressive fibrosing interstitial lung disease.. Eur Respir J 2022 Jun;59(6).
- George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.. Lancet Respir Med 2020 Sep;8(9):925-934.
- Johannson KA, Kolb M, Fisher JH, Walsh SLF. Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse.. Am J Respir Crit Care Med 2022 Nov 15;206(10):1294-1295.
- Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, Vo V, Renzoni EA, Wells AU, Garcia CK, Chua F, Newton CA, Molyneaux PL, Oldham JM. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.. Am J Respir Crit Care Med 2023 Jan 1;207(1):69-76.
- Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.. Am J Respir Crit Care Med 2023 Jan 1;207(1):102-105.
- Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, Belloli EA, Padilla M, Behr J, Goeldner RG, Tetzlaff K, Schlenker-Herceg R, Flaherty KR. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.. Eur Respir J 2022 Feb;59(2).
- Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.. Lancet Respir Med 2020 Feb;8(2):147-157.
- Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.. Lancet Respir Med 2021 May;9(5):476-486.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
